Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Enliven Therapeutics, Inc.
Enliven Therapeutics, Inc. ELVN | 0.00 |
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ:
ELVN) with a Buy and raises the price target from $60 to $80.